Stay Up to Date
Featured News
FDA APPROVES OGSIVEO™ (NIROGACESTAT), AS THE FIRST MEDICAL THERAPY FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMORS.
Filter by:
February 27, 2023
Update: Springworks Therapeutics Has Announced FDA acceptance And Priority Review Of The New Drug Application For Nirogacestat
Clinical Trials December 27, 2022
Breaking News: Springworks Therapeutics Announces Submission Of New Drug Application For Nirogacestat To The U.S. FDA
November 22, 2022
Desmoid Tumors In The Spotlight At The 2022 Connective Tissue Oncology Society (CTOS) Conference
October 27, 2022
DTRF And PeerView Offer CME Accredited Course At CTOS On Treatment Of Desmoid Tumors
Read More about DTRF And PeerView Offer CME Accredited Course At CTOS On Treatment Of Desmoid Tumors
October 20, 2022
DTRF Exec. Dir. Presents At CTOS Webinar On Desmoid Tumors, The CTOS 2022 “Sarcoma Of The Year”
Research 
